| ［1］ |
Singal AG， Llovet JM， Yarchoan M， et al. AASLD practice guidance on prevention， diagnosis， and treatment of hepatocellular carcinoma［J］. Hepatology， 2023， 78（6）: 1922-1965. DOI: 10.1097/HEP.0000000000000466.
|
| ［2］ |
中华人民共和国国家卫生健康委员会医政司 . 原发性肝癌诊疗指南 （2024 年版 ）［J/OL］. 中华肝脏外科手术学电子杂志 ， 2024，13（4）: 407-449. DOI: 10.3877/cma.j.issn.2095-3232.2024.04.001.Department of Medica Administration of National Health Commission of the People’s Republic of China. Guidelines for the diagnosis and treatment of primary liver cancer （2024 edition） ［J/OL］.Chin J Hepat Surg（Electronic Edition）， 2024， 13（4）: 407-449. DOI:10.3877/cma.j.issn.2095-3232.2024.04.001.
|
| ［3］ |
Toh MR， Wong EYT， Wong SH， et al. Global epidemiology and genetics of hepatocellular carcinoma［J］. Gastroenterology， 2023，164（5）: 766-782. DOI: 10.1053/j.gastro.2023.01.033.
|
| ［4］ |
Singal AG， Kanwal F， Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening， prevention and therapy［J］. Nat Rev Clin Oncol， 2023， 20（12）: 864-884. DOI:10.1038/s41571-023-00825-3.
|
| ［5］ |
Vibert E， Schwartz M， Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma［J］. J Hepatol， 2020，72（2）: 262-276. DOI: 10.1016/j.jhep.2019.11.017.
|
| ［6］ |
Renzulli M， Giampalma E. Hepatocellular carcinoma: imaging advances in 2024 with a focus on magnetic resonance imaging［J］.Curr Oncol， 2025， 32（1）: 40. DOI: 10.3390/curroncol32010040.
|
| ［7］ |
Lurje I， Hammerich L. The suppressive tumor microenvironment of AFP-positive hepatocellular carcinoma and its therapeutic implications［J］. Transl Gastroenterol Hepatol， 2023， 9: 1. DOI: 10.21037/tgh-23-81.
|
| ［8］ |
Sangro B， Sarobe P， Hervás-Stubbs S， et al. Advances in immunotherapy for hepatocellular carcinoma［J］. Nat Rev Gastroenterol Hepatol， 2021， 18（8）: 525-543. DOI: 10s.1038/s41575-021-00438-0.
|
| ［9］ |
Finn RS， Qin S， Ikeda M， et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma［J］. N Engl J Med， 2020，382（20）: 1894-1905. DOI: 10.1056/NEJMoa1915745.
|
| ［10］ |
Yau T， Kang YK， Kim TY， et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial［J］. JAMA Oncol， 2020， 6（11）: e204564. DOI: 10.1001/jamaoncol.2020.4564.
|
| ［11］ |
Ren Z， Fan J， Xu J， et al. LBA2 Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma （ORIENT-32）2［J］. Ann Oncol， 2020， 31:S1287. DOI: 10.1016/j.annonc.2020.10.134.
|
| ［12］ |
Kori M， Gov E. Bioinformatics prediction and machine learning on gene expression data identifies novel gene candidates in gastric cancer［J］. Genes， 2022， 13（12）: 2233. DOI: 10.3390/genes13122233.
|
| ［13］ |
Musialik E， Bujko M， Kober P， et al. Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients［J］. Leuk Res， 2014， 38（7）:850-856. DOI: 10.1016/j.leukres.2014.04.013.
|
| ［14］ |
Zhang L， Li J， Xu H， et al. Myc-Miz1 signaling promotes selfrenewal of leukemia stem cells by repressing Cebpα and Cebpδ［J］.Blood， 2020， 135（14）: 1133-1145. DOI: 10.1182/blood.2019001863.
|
| ［15］ |
Chaudhary KR， Kinslow CJ， Cheng H， et al. Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer［J］. Sci Rep， 2022， 12（1）: 10140. DOI: 10.1038/s41598-022-14448-8.
|
| ［16］ |
Roy A， Chakraborty AR， DePamphilis ML. PIKFYVE inhibitors trigger interleukin-24-dependent cell death of autophagydependent melanoma［J］. Mol Oncol， 2024， 18（4）: 988-1011. DOI:10.1002/1878-0261.13607.
|
| ［17］ |
Yang LI， Deng K， Mou Z， et al. Pathological images for personal medicine in Hepatocellular carcinoma: cross-talk of gene sequencing and pathological images［J］. Oncol Res， 2023， 30（5）: 243-258. DOI:10.32604/or.2022.027958.
|
| ［18］ |
Xu B， Peng Z， An Y， et al. Identification of energy metabolism-related gene signatures from scRNA-seq data to predict the prognosis of liver cancer patients［J］. Front Cell Dev Biol， 2022， 10: 858336. DOI:10.3389/fcell.2022.858336.
|
| ［19］ |
Liu YX， Song JL， Li XM， et al. Identification of target genes coregulated by four key histone modifications of five key regions in hepatocellular carcinoma［J］. Methods， 2024， 231: 165-177. DOI:10.1016/j.ymeth.2024.09.017.
|
| ［20］ |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma［J］. J Hepatol， 2025， 82（2）: 315-374. DOI: 10.1016/j.jhep.2024.08.028.
|
| ［21］ |
Qin S， Ren Z， Feng YH， et al. Atezolizumab plus bevacizumab versus sorafenib in the Chinese subpopulation with unresectable hepatocellular carcinoma: phase 3 randomized， open-label IMbrave150 study［J］. Liver Cancer， 2021， 10（4）: 296-308. DOI:10.1159/000513486.
|
| ［22］ |
Zhang X， Zhang M， Sun H， et al. The role of transcription factors in the crosstalk between cancer-associated fibroblasts and tumor cells［J］.J Adv Res， 2025， 67: 121-132. DOI: 10.1016/j.jare.2024.01.033.
|
| ［23］ |
Park H， Lee S， Lee J， et al. Exploring the JAK/STAT signaling pathway in hepatocellular carcinoma: unraveling signaling complexity and therapeutic implications［J］. Int J Mol Sci， 2023，24（18）: 13764. DOI: 10.3390/ijms241813764.
|
| ［24］ |
Li X， Han M， Zhang H， et al. Structures and biological functions of zinc finger proteins and their roles in hepatocellular carcinoma［J］.Biomark Res， 2022， 10（1）: 2. DOI: 10.1186/s40364-021-00345-1.
|
| ［25］ |
Feng Y， Wang P， Cai L， et al. 3D-epigenomic regulation of gene transcription in hepatocellular carcinoma［J］. Adv Genet， 2022， 3（4）:2100010. DOI: 10.1002/ggn2.202100010.
|
| ［26］ |
Xu C， Xu Z， Zhang Y， et al. β-Catenin signaling in hepatocellular carcinoma［J］. J Clin Invest， 2022， 132（4）: e154515. DOI: 10.1172/JCI154515.
|
| ［27］ |
Kong M， Shi X， Gao J， et al. BTF3 affects hepatocellular carcinoma progression by transcriptionally upregulating PDCD2L and inactivating p53 signaling［J］. Mol Med， 2024， 30（1）: 252. DOI:10.1186/s10020-024-01044-x.
|
| ［28］ |
Zhou Y， Zhang S， Qiu G， et al. TSC/mTORC1 mediates mTORC2/AKT1 signaling in c-MYC-induced murine hepatocarcinogenesis via centromere protein M［J］. J Clin Invest， 2024， 134（22）: e174415. DOI:10.1172/JCI174415.
|
| ［29］ |
Zhu H， Yan F， Yuan T， et al. USP10 promotes proliferation of hepatocellular carcinoma by deubiquitinating and stabilizing YAP/TAZ［J］. Cancer Res， 2020， 80（11）: 2204-2216. DOI: 10.1158/0008-5472.CAN-19-2388.
|
| ［30］ |
Lum LS， Sultzman LA， Kaufman RJ， et al. A cloned human CCAAT-box-binding factor stimulates transcription from the human hsp70 promoter［J］. Mol Cell Biol， 1990， 10（12）: 6709-6717. DOI: 10.1128/mcb.10.12.6709-6717.1990.
|
| ［31］ |
Tsukada J， Yoshida Y， Kominato Y， et al. The CCAAT/enhancer （C/EBP） family of basic-leucine zipper （bZIP） transcription factors is a multifaceted highly-regulated system for gene regulation［J］.Cytokine， 2011， 54（1）: 6-19. DOI: 10.1016/j.cyto.2010.12.019.
|
| ［32］ |
Imbriano C， Bolognese F， Gurtner A， et al. HSP-CBF is an NF-Y-dependent coactivator of the heat shock promoters CCAAT boxes［J］.J Biol Chem， 2001， 276（28）: 26332-26339. DOI: 10.1074/jbc.M101553200.
|
| ［33］ |
Chen Y， Gao L， Lin T， et al. C/EBPZ modulates the differentiation and proliferation of preadipocytes［J］. Int J Obes， 2022， 46（3）: 523-534. DOI: 10.1038/s41366-021-01020-z.
|